Table 1

Characteristics of patients initiated onto HCV treatment in Scotland, in the 4 (financial) years prior to and postintroduction of DAAs

Financial year (April to March) of HCV treatment initiationTotal
Pre-DAA eraDAA era
2010/112011/122012/132013/142014/152015/162016/172017/18
Total initiated, N11049100210521054129717821751208211 069
Total initiated (and on clinical database*), N2 (% of N1)967 (92)938 (94)1014 (96)943 (89)1192 (92)1642 (92)1632 (93)1924 (92)10 252 (93)
Characteristics, n (% of N2)
SexFemale236 (24)244 (26)277 (27)249 (26)294 (25)472 (29)421 (26)549 (29)2742 (27)
Male731 (76)694 (74)737 (73)694 (74)898 (75)1170 (71)1211 (74)1375 (71)7510 (73)
Age (years) at treatment initiation†<35303 (31)267 (28)259 (26)272 (29)212 (18)213 (13)219 (13)297 (15)2042 (20)
35–49498 (51)506 (54)538 (53)500 (53)590 (49)777 (47)857 (53)1086 (57)5352 (52)
50+166 (17)165 (18)216 (21)170 (18)389 (33)650 (40)556 (34)541 (28)2853 (28)
GenotypeG1411 (43)359 (38)485 (48)428 (45)519 (44)948 (58)905 (56)926 (48)4981 (49)
G3496 (51)507 (54)450 (44)432 (46)558 (34)565 (34)578 (35)840 (44)4426 (43)
Other/NK57 (6)72 (8)79 (8)83 (9)115 (10)129 (8)149 (9)158 (8)842 (8)
Compensated cirrhosis at treatment initiationNo867 (91)829 (88)855 (84)792 (84)800 (67)1146 (70)1222 (75)1539 (80)8050 (78)
Yes100 (10)109 (12)159 (16)151 (16)392 (33)496 (30)410 (25)385 (20)2202 (22)
Treatment regimen¶IFN-based967 (100)924 (99)1000 (99)907 (96)416 (35)210 (13)117 (7)17 (1)4558 (44)
IFN-sparing0 (NA)6 (<1)0 (NA)15 (2)450 (38)251 (15)151 (9)16 (1)889 (9)
IFN-free0 (NA)8 (<1)14 (1)21 (2)326 (27)1181 (72)1364 (84)1891 (98)4805 (47)
  • *Data collated from 17/18 HCV treatment clinics in Scotland; aggregate data for the remaining clinic sourced for the Scotland total.

  • †Data missing for five patients.

  • §

  • ¶ IFN-based includes pegylated IFN+ribavirin±telaprevir/boceprevir; IFN-sparing includes pegylated IFN+ribavirin+sofosbuvir and pegylated IFN+ribavirin+simeprevir; IFN-free includes any treatment regimen not containing IFN.

  • IFN, interferon; NA, not applicable; NK, not known.